Table 1 Participant characteristics in the total cohort and the immunogenicity subcohort

Baseline demographic and clinical characteristics

Age (year)

-

38.23 ± 9.73

38.90 ± 9.04

Sex (Female, %)

-

148 (70.8)

86 (68.8)

PMH

negative

164 (78.5)

103 (82.4)

thyroid disorder

13 (6.2)

7 (5.6)

CVDRFs ^†

14 (6.7)

5 (4.0)

migraine

3 (1.4)

2 (1.6)

asthma

2 (1.0)

2 (1.6)

other

14 (6.7)

6 (4.8)

Habitual history

negative

177 (84.7)

108 (86.4)

smoking

20 (9.6)

10 (8.0)

alcohol

7 (3.3)

1 (0.8)

hookah

11 (5.3)

6 (4.8)

MS-related characteristics

MS phenotype

RRMS

168 (80.4)

98 (78.4)

SPMS

23 (11.0)

15 (12.0)

PPMS

18 (8.6)

12 (9.6)

Age of disease onset (y/o)

-

29.73 ± 8.82

30.62 ± 8.90

Disease duration (year)

-

8.57 ± 7.13

8.32 ± 6.40

EDSS

-

1.85 ± 1.87

2.00 ± 1.91

Disease-modifying therapies

Not receiving DMT

14 (6.7)

8 (6.4)

Rituximab

45 (21.5)

30 (24.0)

Fingolimod

37 (17.7)

21 (16.8)

Dimethyl fumarate

26 (12.4)

16 (12.8)

Natalizumab

8 (3.8)

5 (4.0)

Ocrelizumab

1 (0.5)

1 (0.8)

IFN-β − 1a

40 (19.1)

23 (18.4)

IFN-β − 1b

15 (7.2)

8 (6.4)

Glatiramer acetate

20 (9.6)

12 (9.6)

Teriflunomide

3 (1.4)

1 (0.8)

COVID-19 related characteristics

COVID-19 before vaccination

definite

38 (18.2)

N/A

suspected

33 (15.8)

N/A

COVID-19 severity (n = 71)

asymptomatic

3 (4.2)

N/A

mild

51 (71.8)

N/A

moderate

12 (16.9)

N/A

severe

4 (5.6)

N/A

critically ill

1 (1.4)

N/A